Verinurad

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameVerinurad
Drug Alias Nameverinurad (RDEA3170)RDEA-3170
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUric acid transporter 1 inhibitors
TargetsUric acid transporter 1
Therapy Area/IndicationsHyperuricemiaDiabetes Mellitus, Type 2Heart Failure, Diastolic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca Plc
Inactive CompaniesArdea Biosciences Inc
Active IndicationsHeart Failure, DiastolicRenal Insufficiency, Chronic
Inactive IndicationsHyperuricemiaDiabetes Mellitus, Type 2Albuminuria +[4] 

Other Information

ATC CodeN/A
Related LinksN/A